FCGR3A and neoplasm: Relevant for potential use in tumor therapy is that SELF-modified IgG1 mAbs also demonstrated a significant lower binding to one FcγRIIIA polymorphism variant and only minor alterations to FcγRI and FcγRIIA [93].